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Human T cell leukemia virus types 1 and 2 (HTLV-1 and HTLV-2) are genetically related complex retroviruses that are capable
of immortalizing human T-cells in vitro and establish life-long persistent infections in vivo. In spite of these apparent similarities,
HTLV-1 and HTLV-2 exhibit a significantly diﬀerent pathogenic potential. HTLV-1 is recognized as the causative agent of adult T-
cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-1-associatedmyelopathy (TSP/HAM). In contrast, HTLV-
2 has not been causally linked to human malignancy, although it may increase the risk of developing inflammatory neuropathies
and infectious diseases. The present paper is focused on the studies aimed at defining the viral genetic determinants of the
pathobiology of HTLV-1 and HTLV-2 through a comparison of the expression strategies and functional properties of the diﬀerent
gene products of the two viruses.
1. Introduction
Human T-cell leukemia virus types 1 and 2 (HTLV-1 and
HTLV-2) are related deltaretroviruses [1] with similar genetic
organization [2–7]. The two viruses share an average 65%
homology at the nucleotide level, with higher conservation
in the gag, pol, env, and tax/rex genes and lower in the long
terminal repeats (LTR), protease, and proximal “X region,” a
region located at the 3′ end of the genome.
Although both viruses immortalize T cells in culture and
establish life-long persistent infections in vivo, they exhibit
a significantly diﬀerent pathogenic potential. HTLV-1 is rec-
ognized as the causative agent of adult T-cell leukemia/lym-
phoma (ATLL) and tropical spastic paraparesis/HTLV-1-
associated myelopathy (TSP/HAM). In contrast, HTLV-2 has
not been causally linked to human malignancy. However,
large cohort studies revealed that HTLV-2 infection may
be associated with lymphocytosis, increased risk of devel-
oping inflammatory neuropathies, infectious diseases, and
with increased all-cause mortality [4–6, 8]. Furthermore,
coinfection with HTLV-2 plays an important role in the pro-
gression of HIV-infected patients to AIDS [9].
In the present paper, we will focus on the discussion of
studies aimed at comparing the expression strategies, regula-
tion, and pathogenic properties of HTLV-1 and HTLV-2.
2. The Genetic Organization and Expression
Strategy of HTLV-1 and HTLV-2
Like other complex deltaretroviruses, HTLV-1 and HTLV-
2 are characterized by the presence of the “X region,” in
addition to the LTR and the gag, pol, and env genes present in
all retroviruses. The coding potential of the HTLV genomes is
greatly enhanced by several expression strategies that include
ribosomal frame shifting (which generates a Gag-Pro-Pol
polyprotein) and alternative splicing (which produce distinct
mRNAs coding for Env and the proteins coded by the X
region) (Figure 1); in addition, some of the alternatively
spliced transcripts are polycistronic [3, 10, 11]. Recent
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Figure 1: Comparison of the organization, alternative splicing, and coding potential of HTLV-1 and HTLV-2 mRNAs. Exon composition
and coding potential of HTLV-1 and HTLV-2 alternatively spliced mRNAs. ORFs are indicated by colored boxes. Splice sites are indicated by
numbers. n.d.: not determined.
studies showed that HTLV-1 and HTLV-2 also produce
complementary-strand mRNAs, transcribed by promoters in
the 3′ LTR; these genes were termed HBZ (HTLV-1 bZIP
factor) and APH2 (anti-sense protein of HTLV-2), respec-
tively [12, 13].
Transcription from the 5′LTR promoter generates 3 ma-
jor size classes of mRNAs (Figure 1): (a) full-length (9 kb)
genomic mRNA, coding for Gag-Pro-Pol; (b) 4 kb singly-
spliced mRNAs, coding for the envelope glycoproteins (Env);
(c) mRNAs of approximately 2 kb encoding proteins of
the X region. The X regions of HTLV-1 and HTLV-2
encode, respectively, four and fivemajor open reading frames
(ORFs), termed x-I through x-V. The x-III and x-IV ORFs
code for the essential regulatory proteins Tax and Rex that
are produced from a dicistronic doubly spliced mRNA con-
taining exons 1, 2, and 3. Tax and Rex provide, respectively,
a positive feedback loop that drives transcription of the
viral genome [2] and a posttranscriptional regulatory loop
enhancing the nuclear export and expression of a subset of
mRNAs [14, 15] (see paragraphs below for details). Other
transcripts of the 2 kb class encode the accessory proteins
of the X region; these transcripts include singly spliced
mRNAs coding for p21rex, p12, and p13 (HTLV-1), tRex and
p28 (HTLV-2) and doubly-spliced mRNAs, coding for the
accessory proteins p30tof (HTLV-1), p10, and p11 (HTLV-2)
[3, 10, 11]. Most of the regulatory and accessory proteins of
the two viruses were shown to share structural and functional
homologies, while p13 and p8 appear to be unique forHTLV-
1 and p11 for HTLV-2 (Table 1).
The discovery of the complex coding potential of del-
taretroviruses also raised the question as to whether the
diﬀerent genes are expressed with a particular temporal seq-
uence and whether diﬀerent patterns of viral gene expression
are associated with diﬀerent disease outcomes. The temporal
sequence of HTLV-1 gene expression has recently been inves-
tigated using splice site-specific real-time RT-PCR (qRT-
PCR) in an ex vivo virus reactivation model based on the
depletion of CD8+ T cells from unstimulated peripheral
blood mononuclear cells (PBMCs) isolated from HTLV-1-
infected patients [16]. The results indicated a “two-phase”
kinetics with tax/rex expression preceding that of other viral
transcripts, a finding that is consistent with the key role of
Tax as a master regulator driving overall viral gene expres-
sion and suggests an “early-late” switch in HTLV-1 gene
expression. Studies in HeLa cells transfected with HTLV-1
molecular clones demonstrated the strict Rex-dependency
of this “two-phase” kinetics [16]. Mathematical modelling
revealed that the observed “two-phase” kinetics was critically
dependent on a delay of Rex function compared to Tax [17],
a prediction that was supported by experimental evidence
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Table 1: Regulatory and accessory proteins coded by HTLV-1 and HTLV-2. The proteins with recognized functional analogies in the two
viruses are indicated in bold. p8 and p13 proteins (indicated in bold italic) are unique to HTLV-1; p11 (indicated in italic) is unique to
HTLV-2.
ORF x-I ORF x-II ORF x-III ORF x-IV ORF x-V Minus strand
HTLV-1 p12, p8 p30, p13 Rex, p21Rex Tax — HBZ
HTLV-2 p10 p28 Rex, tRex Tax p11 APH-2
demonstrating a delayed accumulation and longer half-life
of Rex compared to Tax [16]. More recently, we also analyzed
the expression kinetics of HTLV-2 mRNAs in chronically
infected cell lines and in PBMCs obtained from HTLV-2-
infected patients. Results indicated a “two-phase” expression
kinetics that is reminiscent of that of HTLV-1. Furthermore,
this study revealed that HTLV-2 expresses higher levels of
mRNAs encoding inhibitors of Tax and Rex, that is, p28 and
truncated isoforms of Rex (tRex), respectively (Bender et al.,
submitted), suggesting that HTLV-2 may be characterized by
a more latent expression profile, compared to HTLV-1.
3. Functional Comparison of Tax-1 and Tax-2
HTLV-1 and HTLV-2 Tax (Tax-1 and Tax-2) are required for
viral replication, acting as transactivators of proviral tran-
scription from the 5′LTR. Tax may also enhance HBZ tran-
scription through the 3′LTR, although this eﬀect is weaker
compared to that on the 5′LTR [18, 19].
In addition to these eﬀects on viral transcription, Tax has
a pivotal role in the immortalization and transformation of
infected cells by enhancing the expression of cellular genes
that control T-cell proliferation and by interacting with pro-
teins that control mitotic checkpoints and inactivate tumor
suppressors pathways [20–23]. Tax-1 and Tax-2 present an
overall structural and functional homology, although some
domains and activities appear to be distinct in the two
proteins [24, 25]. Tax-1 is a 353 amino acids (aa), 40 kDa
protein, highly conserved in all HTLV-1 serotypes. Tax-2 has
been characterized mainly from HTLV-2 subtypes A and B
[26]. Tax-2B has 356 aa residues, whereas Tax-2A presents
a 25 aa C-terminal truncation. Tax-1 and Tax-2B share an
amino acid similarity of 85% and have several common
domains including a cyclic AMP response element-binding
protein, (CREB-) binding domain, a zinc-finger, domains
required for interaction with proteasomal subunits, with
transcriptional coactivators and with proteins involved in
transcription, cell cycle progression, and in cell signaling
regulation [5]. The C-terminal region of both Tax-1 and Tax-
2 includes a CREB-activating domain [5, 27]. The central
portion of Tax-1 includes two leucine zipper-like regions
(LZR), necessary for DNA interaction and for protein dimer-
ization [28, 29], binding domains for proteins involved in
chromatin remodeling, cell cycle control, NF-κB activation,
and p300 binding. The main structural diﬀerence between
Tax-1 and Tax-2 is represented by the lack in Tax-2 of a
leucine zipper region which is responsible for noncanonical
NF-κB activation [30–32] and of the C-terminal motif, which
mediates association with protein containing PDZ domains
[24] (Figure 2).
Based on the initial studies on the subcellular localization
of Tax-1 and Tax-2 indicating that Tax-1 was localized in the
nucleus [33] and Tax-2 in the cytoplasm [34], detailed stud-
ies have been devoted to the characterization of the nuclear
localization signal of both proteins. A nuclear localization
signal (NLS) has been mapped to the first 60 aa of Tax-1
[35, 36] and in the first 42 aa of Tax-2 [37]; an additional
NLS, located at position 89–113 of Tax-2, is responsible for
the divergent cellular localization compared to Tax-1 [34].
Tax-1 localizes mainly in nuclear bodies in which two
subunits of NF-κB (p50 and RelA) are present [38]; in the
cytoplasm, Tax-1 localizes in organelles associated with
secretory pathways [39], in structures associated to the mi-
crotubule organizing center (MTOC) [40], and in the cell
to cell contact regions termed virological synapses [41].
Interestingly, the posttranslational modification of Tax is tied
to its subcellular localization and ability to activate the NF-
κB pathway, a key step in HTLV-1-mediated transformation.
In particular, ubiquitinated Tax binds and colocalizes IKK
subunits at a centrosome-associated signalosome leading to
the release of active IKK [42, 43]. Using live-cell imaging,
Kfoury et al. also showed that Tax shuttles among nuclear
bodies and the centrosome, depending on its ubiquitination
and SUMOylation [44]. In contrast, Tax-2 is more abundant
in the cytoplasm [34, 37]. Additional functional properties of
Tax proteins derive from their eﬀects in the reorganization of
TAB2-containing cytoplasmic structures which include RelA
and calreticulin [45].
Both Tax-1 and Tax-2 are necessary and suﬃcient for
HTLV-mediated immortalization of primary human T cells
[46, 47]. Moreover, Tax-1 induces an ATLL-like T-cell malig-
nancy in transgenic mice [48]. Tax-1 induces IL-2 expression
through the transcription factor NFAT in Jurkat cells follow-
ing stimulation by TPA [49] and upregulates the expression
of additional genes encoding cytokines, chemokines, cell
surface ligands, and their receptors [24]. Unlike Tax-1, Tax-2
activates IL-2 gene expression through NFAT, even without
additional stimulation [24, 50].
Tax-1 alters several cellular signaling pathways by inter-
acting with the cellular transcription factors NF-κB, CREB,
serum responsive factor (SRF), and activator protein 1 (AP-
1), that control cell proliferation, intracellular protein distri-
bution, cell migration, apoptosis, and genetic stability [51].
More than 100 proteins have been shown to interact with
Tax-1 [22]. Comparative studies showed that both Tax-1 and
Tax-2 constitutively activate the canonical NF-κB pathway
by interacting with RelA and the IκB kinase complex (e.g.,
IKKα, IKKβ, and NEMO/IKKγ) [22, 52]. Interestingly, Tax-
1, but non Tax-2, also activates the noncanonical NF-κB by
enhancing p100 processing and nuclear translocation of p52
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Figure 2: Schematic representation of Tax-1 and Tax-2 structural and functional domains. The positions of the amino acids modified by
ubiquitination, sumoylation, acetylation, and phosphorylation are indicated.
[31]. Tax-1 and Tax-2 also diﬀer in their mechanism of LTR
transactivation, as Tax-1 recruits the CBP, p300, and PCAF
coactivators factors, whereas Tax-2 does not require PCAF
[53].
Compared to Tax-2, Tax-1 shows an overall higher activ-
ity as a transactivator and in transformation capacity as well
as inhibition of p53 functions [33, 54, 55]. In contrast to
Tax-1, Tax-2 is unable to induce micronuclei [56], does not
perturb development and maturation of pluripotent hema-
topoietic progenitor cells [57], and does not induce G0/G1
cell cycle arrest [58].
4. Rex-1 and Rex-2
Expression of complex retroviruses is controlled at the post-
transcriptional level by viral-encoded regulatory proteins
that actively transport intron-containing mRNAs in the
cytoplasm. In HTLVs, this function is carried out by Rex,
that is produced by a doubly spliced dicistronic mRNA that
also encodes Tax. HTLV-1 Rex (Rex-1) is a 27 kDa, 189 aa
protein; HTLV-2 Rex (Rex-2) is a 170 aa, 26/24 kDa protein
that shares 60% homology with Rex-1 at the amino acid level
(Figure 3). Both Rex-1 and Rex-2 are phosphoproteins that
localize to nucleus, nucleoli, and nucleolar speckles [3, 59–
62]. Although mainly detected in the nuclear compartment,
Rex actively shuttles between the nucleus and the cytoplasm
[60, 63], a property that is intimately linked to its ability to
transport incompletely spliced viral RNA form the nucleus
to the cytoplasm.
The function of Rex-1 is mediated through binding to a
254-nucleotide stem-loop cis acting RNA element termed the
Rex-responsive element (RXRE-1) [64] present in the U3/R
region of the LTR. Due to the positions of the transcription
start site, major splice donor, and polyadenylation signal/site,
the full-length RXRE is located at the 3′ end of all HTLV-
1 transcripts, while the 226 nt- Rex-2 responsive elements
(RXRE-2), which maps to the R/U5 region, is located at
the 5′ end of the unspliced HTLV-2 mRNA (Figure 4) [65–
67]. Furthermore, the ability of the RXRE-1 to fold into
stem loop structure brings the polyadenylation signal into
close proximity to the GU rich polyadenylation site [68, 69]
ensuring eﬃcient polyadenylation of viral mRNAs.
AlthoughRex is not required for cellular immortalization
in vitro, it is necessary for infectivity and viral persistence
in vivo [70], since expression of the viral RNAs encoding
the structural proteins is Rex dependent. Therefore, the Rex-
RXRE interaction was proposed to act as a molecular switch
controlling the transition between productive and latent
phases of HTLV-1 infection, an hypothesis that is consistent
with results of studies of the kinetics of expression of HTLV-1
mRNA (see above) [16].
The domain structure of Rex-1 and Rex-2 is similar,
with NLS, RNA binding domains (RBD), multimerization
domains, and nuclear export signals (NES) (Figure 3). The
N-terminal arginine-rich region (amino acids 1–19) acts
as nuclear localization signal (NLS) [61, 71] and as RNA
binding domain (RBD) which mediates Rex binding to the
RXRE [72]. A leucine-rich sequence located near the middle
of the protein (Rex-1 aa 79–99; Rex-2 aa 81–94) functions
as activation domain (AD) [73] and contains the nuclear
export signal (NES) [63, 74]. The NES interacts with the
protein chromosome regionmaintenance interacting protein
1 (CRM1/exportin 1) and allows export of the Rex-viral
mRNA complex from the nucleus to the cytoplasm [75].
CRM1 belongs to the importin-β family, whose members act
as RNA transporters between the nuclear and cytoplasmic
compartments [76]. Mutations of the four leucine residues
within the NES demonstrate that they are critical for
nuclear export of mRNA [63, 74]. In addition, a unique
C-terminal domain has been described for Rex-2 that is a
target for serine phosphorylation and may also contribute to
eﬃcient nucleocytoplasmic shuttling [60]. The two regions
flanking the NES (aa 57–66 and 106–124 for Rex-1; aa 57–
71 and 124–132 for Rex-2) are required for the assembly of
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Rex into multimeric structures upon binding to the RXRE
[75, 77], a process that is critical for the nuclear export
of viral mRNA since multimerization-defective mutants of
Rex act as dominant-negative mutants [77]. The multimer-
ization of Rex on the viral mRNAs is also enhanced by
CRM1 [78, 79] and by the translation-initiation factor eIF-
5A [80].
Following Rex-RXRE binding and Rex multimerization,
CRM1 is recruited into the complex [75], binds to RanGTP,
and translocates the Rex-mRNA complex across the nuclear
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pore by interacting with nucleoporins. In the cytoplasm,
RanGTP is then converted to RanGDP and is released from
the Rex-mRNA complex. Other proteins aﬀecting Rex func-
tion include Ran binding protein 3 (RanBP3), a scaﬀold
protein that stabilizes the RanGTP-CRM1-Rex-mRNA com-
plex in the nucleus [78, 81] and SRC-associated in mitosis
68 (Sam 68), which increases the Rex-mRNA binding in a
CRM1-independent fashion [82].
In addition, to these eﬀects on viral gene expression, Rex-
1 enhances Tax-mediated upregulation of IL-2 and stabilizes
the IL-2Rα mRNA [83, 84], thus possibly contributing to
transformation of HTLV-1 infected cells. Rex may also en-
hance the expression of FynB, a src family tyrosine kinase
that regulates T-cell receptor stimulation [85, 86] as well as
VCAM-1 and LFA-3 [87], two surface molecules important
in T-cell adhesion and proliferation. More recently Rex-
1 was shown to inhibit the RNA silencing pathway by
interacting with Dicer, a member of the RNase III family
that converts the double-stranded short hairpin RNA to the
single-stranded siRNA (small interfering RNA) [88].
Furthermore, hnRNP A1 (heterogeneous nuclear ribo-
nucleoprotein A1) impairs the posttranscriptional regulation
of HTLV-1 gene expression, by interfering with the binding
of Rex to the RXRE [89]. Knockdown of hnRNP A1 expres-
sion in the chronically infected T-cell lines C91PL using
siRNA increased the levels of the unspliced gag/pol mRNA
in the nucleus (2-fold) and cytoplasm (3-fold), while a more
modest increase of the tax/rex mRNAs was observed in both
compartments and the expression and distribution of the env
mRNA was not significantly altered [90].
5. Cis Acting Regulatory Elements Important
for Rex Function
The expression of the alternatively spliced mRNAs of HTLV-
1 and HTLV-2 is controlled by the relative influence of pos-
itive and negative sequences present on the primary tran-
script. Two major types of RNA cis acting elements have
been described: (i) the RXRE (described above) which me-
diates Rex-dependent nuclear export and (ii) cis acting
repressive sequences (CRS) that determine poor stability
and/or ineﬃcient nucleocytoplasmic export. Although the
general layout and function of these elements are similar
between the two viruses, several interesting diﬀerences can
be pointed out (Figure 4) [91–93].
Studies based on heterologous reporter plasmids mapped
a CRS in the U5 region of HTLV-1 [93, 94]. Due to the posi-
tions of the transcription start site, major splice donor and
polyadenylation signal/site, the HTLV-1 CRS is present only
at the 5′ end of the unspliced mRNA (Figure 4). Interestingly,
an additional CRS at the 3′ end of all transcripts overlaps
the RXRE and acts synergistically with the 5′-CRS. Confocal
microscopy analysis indicated that both the 5′ and 3′ CRSs
act at the posttranscriptional level, most likely as nuclear
retention sequences. Deletion of both the 5′ and the 3′ CRS
resulted in constitutive Rex-independent nuclear export and
expression of mRNAs. A 5′ CRS acting as a nuclear retention
sequence was also mapped in the R-U5 region of HTLV-2
[65]. As the 5′ CRS does not bind Rex-1 [66, 95–97], its
inhibitory function is likely to be mediated by other viral
and/or cellular RNA-binding proteins.
A further layer of complexity is added by a study that
analyzed the postsplicing steps of HTLV-1 regulation by
testing the expression of individual full length viral mRNAs
in their intronless form. Results of this study showed that
mRNA 1–3 (encoding p21rex), mRNA 1-2-3 (encoding Tax
and Rex), and mRNA 1-2-B (encoding p30/tof) were inef-
ficiently expressed when transcribed in their intronless form.
The defective expression of these mRNAs was due to the
inhibitory activity of the RXRE and the lack of a 5′ intronic
region that counteracted the inhibitory eﬀect of the RXRE.
This cis acting stimulatory element (CSE) was mapped to
the major splice donor and sequences overlapping with, but
functionally distinct from, a previously described transcrip-
tional enhancer [98].
In addition to the CRS, other cis acting inhibitory
elements (CIEs) were mapped within the gag-pol and env
regions of the HTLV-1 genome [99]. The inhibitory eﬀect of
these regions is counteracted by binding of Rex to the RXRE,
although it is not clear whether their mechanism of function
is mainly at the level of RNA stability or nucleocytoplasmic
export. At present, no intragenic CIEs have been described in
HTLV-2.
6. Truncated Isoforms of Rex
Both HTLV-1 and HTLV-2 produce truncated isoforms
of Rex which lack the N-terminal arginine-rich RBD/NLS
and are therefore predicted to be incapable of binding the
RXRE and accumulate in the nuclear compartment. HTLV-
1 produces a single truncated x-III ORF product termed
p21rex, which also lacks the oligomerization domains of
full-length Rex (Figure 3) [100, 101]. It was hypothesized
that p21rex might act as a repressor of full-length Rex, thus
inhibiting the expression of virion-associated proteins and
playing a role as a latency-inducing factor in the HTLV-1 life
cycle [100].
HTLV-2 produces a family of truncated isoforms ranging
from 22 to 17 kDa which diﬀer in the initiation codon usage
and phosphorylation status [59]. These truncated x-III ORF
products of HTLV-2, that we propose to term tRex, are
expressed from two singly spliced mRNAs containing exon
1 linked to either exon 3 or to exon B (Figure 3). Initiation
of translation from the first AUG codon located within
the x-III ORF gives rise to two major protein isoforms of
22 and 20 kDa and a minor 18-kDa protein diﬀering by
posttranslational modification. Translation from the second
AUG of the x-III ORF produces a 17-kDa protein [3, 59].
The multimerization and activation domain of Rex2 are also
present in the 22–20 and 18 kDa tRex proteins. Cotransfec-
tion assays demonstrated that the tRex proteins were able to
inhibit the ability of Rex to activate the expression of a Rex-
dependent mRNA. Subcellular fractionation studies showed
that Rex was preferentially localized in the cytoplasmic or
nuclear fraction depending on its phosphorylation status and
that coexpression of Rex with tRex changed the phospho-
rylation pattern of Rex and intracellular localization of tRex
[59].
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7. Expression and Function of Accessory Genes
Coded in the XRegion ofHTLV-1 andHTLV-2
p30tof and p28 are products of the x-II ORF of HTLV-1 and
HTLV-2, respectively. p30tof is coded by a doubly spliced
mRNA containing exons 1, 2, and B; p28 is coded by 2
singly spliced mRNAs containing exons 1 and 3 or exons
1 and B (Figure 1). The two proteins are both dispensable
for viral propagation in vitro but important for viral spread
and persistence in animal models [102–104]. p30tof and p28
share some functional analogies as they both sequester the
tax/rex mRNA in the nucleus, thus reducing viral expression,
an eﬀect that may result in viral latency and blunt immune
recognition of infected cells [105, 106]. By interacting with
the coactivator CBP/p300 [107, 108], p30tof also aﬀects
Tax-mediated transcription of viral and cellular genes at
the transcriptional and posttranscriptional levels, including
genes involved in T-cell activation and apoptosis [109, 110].
Further studies revealed that p28 function was partly distinct
from that of p30tof in that it was devoid of transcriptional
modulating activity. Moreover, p30tof interacts with the
RNA-binding domain of Rex inhibiting Rex binding to the
RxRE [111, 112]. By interacting with PU.1, p30tof inhibits
its transcriptional activity, resulting in the downregulation of
Toll-like receptor 4 (TLR4) expression from the cell surface
[113], suggesting that the protein might also play a role
in reducing activation of adaptive immunity in HTLV-1-
infected patients.
p13, a short isoform coded by the x-II ORF of HTLV-
1 from a singly spliced mRNA containing exons 1 and C
(Figure 1), corresponds to the C-terminal 87 amino acids of
p30tof [11] and is localized mainly in the mitochondrial
inner membrane [114] and in part to the nucleus [115, 116].
p13 increases mitochondrial permeability to K+ and activates
the electron transport chain, resulting in increased mito-
chondrial reactive oxygen species (ROS) production [117].
These changes in ROS homeostasis aﬀect both cell survival
and proliferation depending on the cell’s inherent ROS set-
point. While in normal resting T-cells, which have low ROS
levels, p13 expression resulted in mitogenic activation, in
cancer cells which are characterized by a high ROS setpoint,
p13 induced cell death [114, 115, 118–121]. So far, no HTLV-
2 ortholog of HTLV-1 p13 has been identified.
HTLV-1 p12 and p8 are coded by the x-I ORF from a
singly spliced mRNA containing exons 1 and A or exons 1
and B (Figure 1). p12 localizes in the endoplasmic reticulum
(ER) and in the Golgi apparatus, where it interacts with the β
and γc chains of the interleukin-2 receptor (IL-2R), reducing
their surface expression [122]. p12 expression results in
activation of STAT-5, which provides a mitogenic signal to
T-cells [123]. p12 also decreases surface expression of MHC-
I, thus contributing to blunt lysis of HTLV-1-infected cells by
CTL [124]. p12 also interacts with calreticulin and calnexin
[125] resulting in increased Ca2+ release from the ER [126]
and activation of the NFAT, a mitogenic pathway in T cells
[127–129]. Within the ER, p12 is cleaved into an 8 kDa pro-
tein (p8) which traﬃcs to the immunological synapse and
favours T-cell anergy. p8 also increases cell-to-cell viral
transmission through the formation of intercellular conduits
among T cells [130, 131]. In analogy to HTLV-1 p12, HTLV-
2 p10 and p11 were shown to bind the MHC heavy chain;
however, p10 and p11 did not bind other targets of p12, such
as the IL2R β chain or the 16-kDa subunit of the vacuolar
H+ ATPase [132]. No functional homologue of p8 has been
described in HTLV-2.
8. Functional Comparison of
Minus-Strand Genes
Transcription from a promoter in the 3′ LTR generates tran-
scripts from the complementary strand which encode the
HBZ (HTLV-1) and APH-2 (HTLV-2) genes [12, 13]. The
negative strand of the HTLV-1 genome [133] generates at
least 2 diﬀerent transcripts, one spliced (hbz sp1) and the
other unspliced (hbz us) [134–136]. Studies in infected cells
indicated that hbz sp1 was more abundant than hbz us [137].
Hbz sp1 has multiple transcriptional initiation sites in the
U5 and R regions of the 3′ LTR, whereas transcription of the
hbz us mRNA initiates within the tax gene. Both hbz sp1 and
hbz us promoters are TATA-less [19]. The transcription of
hbz sp1 is dependent on the Sp1 transcription factor and is
weakly responsive to Tax [19, 138], a finding that is consistent
with the fact that hbz is expressed in HTLV-1-infected cells
regardless of the expression levels of Tax and hbz expression
exhibits a stronger correlation with provirus load than tax
expression. Hbz sp1 is translated into a protein of 206 aa,
while hbz us produces a protein of 209 aa diﬀering by 7 aa
at the N-terminus [135]. The domain structure of the HBZ
protein includes an N-terminal transcriptional activation
domain (AD), a central domain (CD), and a C-terminal
basic ZIP domain (bZIP) [12]. The HBZ SP1 protein is more
abundant and has a longer half-life than the US isoform
[19]. HBZ US protein mainly localizes in nuclear bodies
while HBZ-SP1 is mainly nucleolar; two regions rich in basic
amino acids and a DNA binding domain are associated with
nuclear localization of HBZ [139, 140].
HBZ is not necessary for in vitro transformation but
increases infectivity and viral persistence in in vivo animal
model [141]; furthermore, HBZ was demonstrated to be
oncogenic in a transgenic mouse model [142]. HBZ interacts
with a number of transcription factors. Through interactions
mediated by its bZIP domain, HBZ inhibits the ability
of CREB-2 to bind to the HTLV-1 LTR, resulting in the
inhibition of Tax-mediated transcription from the 5′ LTR
[12]. HBZ interacts with the KIX domain of CBP/p300 via
LXXLL-like motifs in its N-terminal region, leading to sup-
pression of viral transcription by inhibiting the recruitment
of CBP/p300 to the 5′ LTR promoter [143]. In addition, by
forming a trimeric structure with Smad3 and p300, HBZ
enhances TGF-β signalling [144] resulting in upregulation
of Foxp3, a marker characteristic of HTLV-1 infected cells as
well as of Treg cells [142].
HBZ’s bZIP domain also mediates formation of het-
erodimers with c-Jun, JunB, and JunD [145, 146]. Binding of
HBZ to JunB and c-Jun decreases their DNA binding activity
by preventing their interaction with Fos, leading to repres-
sion of the AP-1 complex [147]. Furthermore, HBZmediates
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proteasomal degradation of c-Jun [147] and sequestration of
JunB in nuclear bodies [140]. In contrast, the interaction of
HBZ with Jun-D results in the activation of JunD-dependent
cellular genes, including hTERT, the catalytic subunit of
human telomerase [146, 148]. Through its N-terminal
region, HBZ interacts with IRF-1 (interferon regulatory
factor 1) reducing its DNA-binding ability and its stability,
resulting in a reduction of IRF-1-mediated apoptosis [149].
HBZ inhibits the classical NF-κB pathway by two diﬀerent
mechanisms: by inhibiting the DNA binding of the NF-κB
subunit p65 and by increasing the expression of PDLIM2,
the E3 ubiquitin ligase of p65, leading to enhanced ubiquiti-
nation and degradation of p65 [150]. The downregulation of
the NF-κB pathway was proposed to counteract the onset of
Tax-induced cellular senescence, which results from hyper-
activation of the NF-κB pathway [151]. HBZ expression is
associated with proliferation of ATLL cells in vivo and in vitro
[136, 152]. Mutational analyses showed that the hbz mRNA,
rather than HBZ protein, has a growth-promoting eﬀect
on T cells [136] possibly by up-regulating the transcription
of the E2F1 gene and its downstream targets. Interestingly,
only hbz sp1, not hbz us, promotes proliferation of T-cells,
indicating that the first exon of the hbz sp1 transcript is
critical for this activity [19]. Furthermore it has been shown
that hbz sp1 mRNA promotes Tax expression by repressing
the p30tof, an inhibitor of the tax/rex mRNA; interestingly,
this eﬀect is not mediated by the 5′ stem-loop structure of
hbz [153]. Moreover, the recent finding that over 90% of the
hbz transcripts are localized in the nucleus in the chronically
infected cell line C91PL and inHeLa cells transfected with the
ACH HTLV-1 molecular clone underscores their importance
as noncoding RNAs [16].
Following the discovery of HBZ, an antisense transcript
was identified in HTLV-2 [13]. Its product, coded by an ORF
located between Tax and Env, was named APH-2. Although
the APH-2 mRNA was detected in HTLV-2 infected cell lines
and in HTLV-2-infected patients, a quantitative comparison
of the APH-2 expression levels with proviral loads has not
been reported so far. The APH-2 mRNA is transcribed
from the R and U5 regions of the 3′-LTR, spliced, and
polyadenylated. APH-2 is a 183-aa protein, localized mainly
in the nucleus. Despite the lack of a canonical bZIP domain,
APH-2 interacts with CREB (but not with CBP/p300) and
represses Tax-2-mediated transcription. In analogy to HTLV-
1 hbz, also the APH-2 transcript exhibits a marked nuclear
localization in chronically infected cell lines (Bender et al.,
submitted).
9. Conclusions and Perspectives
HTLV-1 and HTLV-2 are complex retroviruses with similar
genetic structures but significantly diﬀerent pathogenic po-
tential. Many studies were aimed at defining the viral genetic
determinants of these viruses by comparing the expression
strategies and functional properties of the diﬀerent gene
products of the two viruses. Although these studies added
considerable knowledge to the understanding of the HTLV-
1 and HTLV-2 gene expression, important questions still
remain open. The Tax proteins of the two viruses, although
showing many similarities, exhibit some diﬀerences, espe-
cially regarding their capability to activate the NF-kB path-
way and to induce genetic instability. The mechanism of
function of HBZ and APH-2 as noncoding RNAs, which was
underscored by their predominant nuclear localization [16],
also deserves further studies; in particular, it would be inter-
esting to test whether, in analogy tho HBZ, APH-2 may pro-
mote T-cell proliferation and exhibit pathogenic properties
in transgenic mice. Although most of the accessory proteins
appear to be orthologues in the two viruses, p13 and p8 are
peculiar of HTLV-1, while p11 of HTLV-2 does not appear to
have anHTLV-1 orthologue. Further studies should be aimed
at testing whether the functions of these proteins, along
with the diﬀerences in Tax-1 and Tax-2, might contribute
to explain the diﬀerent pathogenic potential of HTLV-1 and
HTLV-2. In both viruses, the Rex-dependence of viral mRNA
is determined by cis acting inhibitory sequences that decrease
mRNA stability and nuclear export. A thorough analysis of
the mechanism of function of these elements, for example,
through a definition of their protein binding partners, is
likely to shed light into the mechanisms controlling mRNA
turnover and nucleocytoplasmic traﬃcking. The complex
and partly redundant splicing pattern of deltaretroviruses
also raises the question as to which mechanism(s) determine
splice site selection, resulting in distinct patterns of viral gene
expression and, possibly, diﬀerent clinical outcomes of HTLV
infection.
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